1.
Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy
by Houot, Roch
Trends in immunology, 2011, Vol.32 (11), p.510-516
2.
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
by Sun, Roger
The lancet oncology, 2018, Vol.19 (9), p.1180-1191
3.
TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma
by Selmi, Abdelkader
Cancer letters, 2014, Vol.357 (1), p.412-418
4.
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-la...
by Marabelle, Aurélien
The lancet oncology, 2020, Vol.21 (10), p.1353-1365
5.
Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics
by Seban, Romain-David
European journal of nuclear medicine and molecular imaging, 2019, Vol.46 (11), p.2298-2310
6.
Tumour mutational burden in treatment-resistant tumours – Authors' reply
by Marabelle, Aurelien
The lancet oncology, 2020, Vol.21 (12), p.e552-e552
7.
Immunosenescence, inflammaging, and cancer immunotherapy efficacy
by Rodriguez, Julieta E
Expert review of anticancer therapy, 2022, Vol.ahead-of-print (ahead-of-print), p.1-12
8.
TWIST1is a direct transcriptional target ofMYCNandMYCin neuroblastoma
by Abdelkader Selmi
Cancer letters, 2015, Vol.357 (1), p.412
